JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Search

Simulations Plus Inc

Suletud

SektorTervishoid

14.6 0.55

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.23

Max

14.86

Põhinäitajad

By Trading Economics

Sissetulek

3.9M

4.5M

Müük

5.9M

24M

Aktsiakasum

0.35

Dividenditootlus

0.48

Kasumimarginaal

18.669

Töötajad

212

EBITDA

4.9M

7.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+9.89% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.24%

Järgmine tulemuste avaldamine

13. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

51M

302M

Eelmine avamishind

14.05

Eelmine sulgemishind

14.6

Uudiste sentiment

By Acuity

21%

79%

52 / 348 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27. apr 2026, 23:08 UTC

Tulu
Suurimad hinnamuutused turgudel

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27. apr 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27. apr 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27. apr 2026, 23:34 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27. apr 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27. apr 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27. apr 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27. apr 2026, 22:10 UTC

Tulu

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27. apr 2026, 21:56 UTC

Tulu

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27. apr 2026, 21:44 UTC

Tulu

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27. apr 2026, 21:43 UTC

Tulu

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. apr 2026, 20:39 UTC

Tulu

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

9.89% tõus

12 kuu keskmine prognoos

Keskmine 16 USD  9.89%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

52 / 348 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat